The addition of enzalutamide to ADT (with or without docetaxel) increases the proportion of patients with mHSPC achieving a PSA nadir of 0.2 or less at 7 months. A PSA nadir of 0.2 ng/mL or less at 7 ...
In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...
PSA nadir 6 months after RT correlated with prostate cancer outcomes at 12 months and 5 years Nadir ≥0.1 ng/mL associated with worse outcomes with RT ± ADT Editorial questions relevance of findings in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results